Allied Health & Imaging · Independent exam preparation
Physician EHRA Invasive Cardiac Electrophysiology: Mechanisms, Mapping and Clinical Decisions Study Guide
Practise rhythm mechanisms, intracardiac maneuvers, ablation endpoints and complication decisions for physician EHRA invasive electrophysiology certification.
By CertMedbry · Updated 1 November 2026
Distinguish tachycardia mechanisms, interpret pacing responses, select meaningful ablation endpoints and recognise complications that require urgent action. This selective guide develops 60 concepts across all eight physician EP blueprint domains, followed by independent questions and recall cards. The official examination outline, entire updated EHRA Core Curriculum and applicable ESC/EHRA guidance define the full preparation scope.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which certification pathway does this guide address?
The English-language EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP). Physician eligibility includes a medical diploma. EHRA separately offers invasive electrophysiology certification for allied professionals (EP/AP), with its own examination and blueprint; that pathway is outside this guide.
EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP) · EHRA Certification in Invasive Cardiac Electrophysiology for Allied Professionals (EP/AP)
How many questions are administered and scored?
The current physician programme page states 130 questions in two parts of 65. It states that the 10 least discriminating questions are excluded after statistical analysis, producing a final score derived from 120 questions, and also describes removal of defective items following review. These exclusions should not be described as 10 designated pretest questions: that designation is not established.
EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP)
How long is the examination?
Each of the two parts lasts three hours, with a one-hour break between them. This gives six hours of examination time and a seven-hour span including the stated break.
EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP)
What are the official item style and delivery arrangements?
The issuer describes English-language clinical-scenario multiple-choice questions with five options and one best answer, without negative marking. Delivery uses online human proctoring on the candidate’s computer through the stated CYIM/ProctorU arrangements. The available programme description does not establish computer-adaptive testing. This guide’s 20 independent drills use four options and do not reproduce the official answer format or predict a passing result.
EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP)
Which blueprint and dates govern this study map?
The issuer’s EHRA_EP_Topics_Distribution.pdf provides eight domains and weight ranges but states no version identifier or effective date and warns that distribution can change. Programme evidence dated 1 November 2026 links the 2024 EHRA Core Curriculum and states that questions cover the entire curriculum. A curriculum publication year does not establish a blueprint effective date.
Certification in Invasive Cardiac Electrophysiology (EP): Topics distribution · EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP) · EHRA Certifications
How is coverage distributed in this guide?
The official ranges are Basic electrophysiology 5–10%, General concepts 5–10%, Supraventricular tachycardias 15–20%, Ventricular tachycardias 15–20%, Specific ablation aspects 10–15%, Atrial flutter and Atrial Fibrillation 15–20%, Clinical rhythmology 10–15%, and Devices 10%. The 60 concepts allocate 4, 4, 10, 9, 8, 10, 9 and 6 respectively. Both the 20-question test and 20-card set allocate 1, 1, 4, 3, 2, 4, 3 and 2 respectively. Each allocation falls within those ranges; topic selection remains selective.
Certification in Invasive Cardiac Electrophysiology (EP): Topics distribution
Does passing the examination complete physician certification?
No. The current programme requires the theoretical examination and a practical-experience logbook for full certification. The historical 2021 editorial describes examination-based Level 1 and practical-experience Level 2. Those historical labels should not substitute for the current programme’s stated requirements.
EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP) · EHRA certification: a 15-year journey of attesting excellence in arrhythmia healthcare
Does EHRA certification confer national practice rights?
The programme describes a competency standard across Europe and beyond, rather than a compulsory regulatory certificate. National laws and regulations determine individual practice and reporting rights. This guide uses ESC/EHRA clinical guidance and does not imply that certification replaces national licensing requirements.
EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP)
Are other languages and a fixed passing percentage established?
The programme also describes a Spanish version developed with LAHRS, whose availability depends on the examination schedule. This guide selects the English-language pathway. The issuer describes standard-setting methods for the passing score but does not provide a fixed universal passing percentage in the supplied programme information.
EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP)
These independently authored learning materials address the physician invasive cardiac electrophysiology pathway. The historical designation EHRA Certified Electrophysiology Specialist (ECES) is documented in the issuer’s 2021 editorial; its mapping to the current physician EP programme is supported by continuity of issuer, specialty and audience, without an established formal renaming date.
Outline used: Undated physician EP examination blueprint, EHRA_EP_Topics_Distribution.pdf; no version identifier or effective date stated. The current programme links the 2024 EHRA Core Curriculum. The issuer's 2021 editorial substantiates EHRA Certified Electrophysiology Specialist (ECES) as a physician credential. This guide maps the assigned ECES label to physician invasive cardiac electrophysiology certification; continuity with the current programme is an evidenced inference, without an established formal renaming date. The separate allied-professional EP/AP examination is excluded.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Basic electrophysiology (genetics, channels, drugs)5–10%
1.Which currents distinguish nodal from working-myocardial depolarisation?
In atrial and ventricular working myocardium, fast sodium current generates the rapid phase-0 upstroke; calcium entry supports the plateau, and potassium currents govern repolarisation. In sinoatrial and atrioventricular nodal tissue, calcium current is central to phase-0 depolarisation. This difference explains why calcium-channel blockade slows AV nodal conduction, whereas sodium-channel blockade particularly affects conduction in working myocardium and the His–Purkinje system. Tissue type therefore helps predict a drug’s electrophysiological effect.
Apply it
During an EP study, an AV nodal blocking drug prolongs AH substantially while HV remains unchanged. Interpret the response as predominantly nodal slowing, rather than assuming that all components of atrioventricular conduction have slowed equally.
Common pitfall: Treating every cardiac action potential as sodium-dependent obscures tissue-specific drug effects and can lead to incorrect localisation of a conduction change during testing.
Practical compendium of antiarrhythmic drugs: an EHRA clinical consensus statement
2.How do early and delayed afterdepolarisations differ?
Early afterdepolarisations interrupt repolarisation during phases 2 or 3, particularly when action potentials are prolonged and repolarisation reserve is reduced. Delayed afterdepolarisations occur after repolarisation and reflect intracellular calcium overload with a transient inward current, including sodium–calcium exchange. Pause-associated torsades suggests an early-afterdepolarisation setting, whereas catecholamine-dependent triggered ventricular ectopy suggests delayed afterdepolarisations. These mechanisms describe triggered activity, which requires a preceding action potential, rather than spontaneous automatic impulse formation.
Apply it
Compare two recordings: polymorphic VT following a long pause and marked QT prolongation, and repetitive outflow-tract ectopy during adrenergic stimulation with a normal QT. Assign the likely triggered mechanism before selecting further diagnostic manoeuvres.
Common pitfall: Calling every catecholamine-sensitive rhythm automatic overlooks calcium-mediated triggered activity. Conversely, a prolonged QT identifies susceptibility but does not prove the mechanism of every observed ventricular beat.
Practical compendium of antiarrhythmic drugs: an EHRA clinical consensus statement
3.Why do use dependence and reverse use dependence matter?
Use-dependent sodium-channel block becomes more pronounced with repeated activation because drug binding and recovery depend on channel state and pacing rate. Flecainide can therefore produce greater QRS widening during tachycardia or exercise. Reverse use dependence describes greater repolarisation prolongation at slower rates with certain potassium-channel blockers, including sotalol. Bradycardia and pauses can consequently increase torsades susceptibility. These are drug-specific behaviours; they should not be assumed to apply uniformly to every antiarrhythmic agent.
Apply it
A patient taking flecainide has modest resting QRS widening but marked widening during exercise. Relate the rate-dependent change to sodium-channel block, then reassess drug safety and underlying conduction or structural disease rather than focusing solely on QT duration.
Common pitfall: Assuming faster rates always increase every drug effect confuses conduction slowing with repolarisation prolongation. Reverse use dependence specifically helps explain pause-related risk with selected agents.
Practical compendium of antiarrhythmic drugs: an EHRA clinical consensus statement
4.How should a genetic variant influence channelopathy assessment?
A genetic result must be interpreted against gene–disease validity, variant classification, phenotype and family segregation. A pathogenic or likely pathogenic variant in an established disease gene can support diagnosis and targeted family evaluation. A variant of uncertain significance does not establish causality and should not independently drive predictive testing or irreversible treatment. Clinical features remain essential: an apparently explanatory variant cannot replace assessment of ECG findings, symptoms, medication effects and alternative acquired causes.
Apply it
An asymptomatic relative has normal repeated ECGs and a family member’s variant classified as uncertain significance. Explain that the variant alone does not establish inherited disease; organise phenotype-based assessment according to the family’s clinical findings.
Common pitfall: Equating a rare variant with a pathogenic variant overstates certainty. Absence of an identified mutation also does not exclude a clinically established inherited arrhythmia syndrome.
2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
General concepts5–10%
5.How do AH and HV intervals localise conduction delay?
The AH interval primarily reflects conduction through the AV node, while the HV interval measures conduction from the recorded His potential to earliest ventricular activation. Incremental atrial pacing commonly lengthens AH because AV nodal conduction is decremental. Disproportionate HV prolongation instead points toward His–Purkinje disease. Interpretation requires reliable electrogram identification and attention to pacing conditions, drugs and pre-excitation, because accessory activation or mislabelled signals can invalidate a simple interval-based conclusion about the site of delay.
Apply it
During atrial pacing, AH progressively prolongs while HV remains stable. Localise the changing delay to the AV node. If a separate patient develops infra-His block despite an intervening His signal, recognise distal conduction-system failure instead.
Common pitfall: Using the surface PR interval alone cannot separate atrial, nodal and His–Purkinje contributions. A visible His signal must also be correctly distinguished from nearby atrial or ventricular components.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy · 2019 ESC Guidelines for the management of patients with supraventricular tachycardia
6.What does an effective refractory period actually measure?
An effective refractory period is defined under a specified stimulation protocol by the longest premature coupling interval that fails to propagate through the tissue being tested. It is not simply action-potential duration. Interpretation depends on whether the stimulus captured locally, whether the impulse conducted downstream and which structure blocked. Drive cycle length, preceding pacing history, autonomic tone and drugs alter refractoriness. A failed response therefore needs local electrogram confirmation before it can be assigned to an accessory pathway or AV node.
Apply it
An atrial extrastimulus produces no ventricular response. First establish that atrial capture occurred. Then inspect His and ventricular signals to distinguish AV nodal block, distal block and loss of accessory-pathway conduction under the chosen pacing protocol.
Common pitfall: Calling absent ventricular activation an accessory-pathway refractory period without confirming atrial capture or excluding another site of block turns a technical observation into an unsupported physiological conclusion.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
7.How does entrainment test proximity to a reentry circuit?
Entrainment captures a reentrant rhythm with pacing faster than its cycle length while the underlying circuit continues. The postpacing interval measures return from the last pacing stimulus to the next local activation. A small postpacing-interval minus tachycardia-cycle-length difference supports proximity to the circuit when capture, measurement and conduction behaviour are valid. Concealed fusion adds information about circuit access. Rate-dependent conduction slowing and remote pacing can lengthen the interval, so a numerical threshold alone cannot establish an indispensable isthmus.
Apply it
During stable scar-related VT, pacing produces concealed fusion and a postpacing interval only slightly longer than the tachycardia cycle length. Combine this result with stimulus-to-QRS timing and local electrograms before treating the site as a candidate circuit isthmus.
Common pitfall: A short postpacing interval supports circuit proximity but does not automatically prove an essential ablation target. Incorrect capture or pacing-induced conduction changes can distort the measurement.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
8.Why can a voltage map misrepresent arrhythmogenic tissue?
Recorded electrogram amplitude depends on viable tissue, electrode size and spacing, catheter contact, activation direction, filtering and rhythm. Low bipolar voltage can identify scar, but poor contact or unfavourable wavefront orientation can mimic abnormal substrate. Conversely, normal endocardial bipolar voltage does not exclude intramural or epicardial disease. Interpret voltage alongside electrogram timing, unipolar information, imaging and clinical context. A coloured map is a measurement-dependent representation rather than a direct histological image of the myocardium.
Apply it
A low-voltage patch disappears when contact improves and the catheter orientation changes. Reassess acquisition quality before labelling scar. In another region, normal bipolar voltage with suspicious CMR findings should prompt consideration of deeper substrate rather than reassurance.
Common pitfall: Applying one voltage cutoff universally ignores electrode geometry, tissue thickness and activation direction. Automatically ablating every low-voltage point can expose patients to unnecessary lesions without identifying a circuit.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
Supraventricular tachycardias15–20%
9.What defines the typical AVNRT circuit?
Typical AV nodal reentrant tachycardia usually conducts antegradely through a slow nodal pathway and retrogradely through a fast pathway. Atrial and ventricular activation therefore occur nearly simultaneously, often producing a short septal VA interval and hidden or terminal retrograde P waves. The atrium and ventricle need not be obligatory circuit components. Slow-pathway modification targets the inferior nodal extension while avoiding the compact AV node, making circuit identification essential before ablation near the conduction system.
Apply it
A regular narrow-complex tachycardia has almost simultaneous septal atrial and ventricular signals. A His-refractory ventricular premature beat does not perturb it. Consider typical AVNRT and seek corroborating pacing evidence before planning slow-pathway modification near the coronary sinus ostium.
Common pitfall: A short RP interval strongly suggests typical AVNRT but is not exclusive to it. Septal accessory pathways and some atrial tachycardias can produce superficially similar recordings.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
10.How does atypical AVNRT present differently?
Atypical AVNRT uses slower retrograde nodal conduction and commonly produces a long RP or VA interval. Fast–slow and slow–slow patterns describe conduction behaviour, but surface timing alone cannot establish the circuit. The differential includes atrial tachycardia and orthodromic AVRT using a slowly conducting accessory pathway. Ventricular pacing responses, atrial activation sequences and corrected timing measurements help discriminate these mechanisms. Earliest atrial activation can vary, so an eccentric sequence does not by itself prove an accessory pathway.
Apply it
A long-RP narrow-complex tachycardia has earliest atrial activation near the coronary sinus ostium. Compare ventricular pacing responses and His-refractory premature-beat effects before choosing between atypical AVNRT, slowly conducting accessory-pathway AVRT and atrial tachycardia in this patient.
Common pitfall: Treating every long-RP tachycardia as atrial tachycardia misses retrograde slow-pathway AVNRT. A posteroseptal earliest atrial signal also does not independently establish a slowly conducting accessory pathway.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
11.What does an AH jump demonstrate?
An abrupt increase in AH during progressively premature atrial stimulation demonstrates discontinuous antegrade AV nodal conduction, consistent with dual-pathway physiology. The premature impulse encounters a refractory fast pathway but conducts through a recovered slow pathway. A nodal echo or sustained tachycardia provides additional evidence of reentry. Dual physiology alone does not establish that a patient’s clinical palpitations are AVNRT: the observed substrate must be related to inducible rhythm, symptoms and the rest of the electrophysiological findings.
Apply it
An atrial coupling interval shortens by 10 ms and AH lengthens by 70 ms, but no tachycardia follows. Recognise dual AV nodal physiology while avoiding a definitive clinical AVNRT diagnosis from that isolated finding alone.
Common pitfall: An AH jump identifies a conduction property, rather than a complete clinical diagnosis. Absence of an obvious jump also does not categorically exclude AVNRT under different stimulation conditions.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
12.How does orthodromic AVRT complete its circuit?
Orthodromic AV reentrant tachycardia usually conducts antegradely through the AV node and His–Purkinje system, then returns to the atrium through an accessory pathway. Ventricular activation is therefore usually narrow unless aberrancy or pre-existing conduction disease is present. The atrium and ventricle form obligatory parts of the circuit. A ventricular premature beat delivered when the His bundle is refractory can expose accessory-pathway participation if it advances atrial activation and resets or terminates the tachycardia.
Apply it
During narrow-complex tachycardia, a His-refractory ventricular premature beat advances the next atrial signal and advances the subsequent His activation. This response supports a participating retrograde accessory pathway, guiding further mapping toward its atrial and ventricular insertion sites.
Common pitfall: A narrow QRS does not exclude an accessory pathway: orthodromic AVRT uses normal ventricular activation. Eccentric atrial activation supports localisation but requires confirmation of circuit participation.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
13.Why does antidromic AVRT produce a wide QRS?
Antidromic AVRT conducts antegradely over an accessory pathway, activating ventricular myocardium outside the normal His–Purkinje entry route. Retrograde return usually uses the AV node or another accessory pathway. The resulting QRS is fully pre-excited and wide. Its differential includes VT and other pre-excited tachycardias, so the surface appearance alone is insufficient. Demonstrating the activation sequence and obligatory circuit components is particularly important before assigning a supraventricular mechanism to an undifferentiated wide-complex rhythm.
Apply it
A regular wide-complex tachycardia occurs in a patient with manifest pre-excitation. Consider antidromic AVRT, but assess haemodynamic status and obtain mechanism-specific evidence rather than assuming that a known accessory pathway makes ventricular tachycardia impossible in this setting.
Common pitfall: Known pre-excitation can anchor interpretation prematurely. An accessory pathway may be a bystander, and VT remains possible even when the resting ECG shows a delta wave.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
14.Why can an accessory pathway be concealed on the resting ECG?
A concealed accessory pathway conducts retrogradely without demonstrable antegrade conduction, so sinus rhythm lacks a delta wave. It can still provide the retrograde limb of orthodromic AVRT. Retrograde atrial activation during ventricular pacing and tachycardia can identify its location and conduction behaviour. Because a truly retrograde-only pathway cannot conduct atrial fibrillation antegradely to the ventricles, its risk profile differs from that of a rapidly conducting manifest pathway, although its associated tachycardia may still require treatment.
Apply it
A patient has recurrent narrow-complex tachycardia but no resting pre-excitation. Ventricular pacing reveals eccentric nondecremental atrial activation, and a His-refractory ventricular beat resets tachycardia. Investigate a concealed pathway rather than excluding AVRT because the baseline ECG is normal.
Common pitfall: Absence of a delta wave does not exclude AVRT. Conversely, apparent absence of pre-excitation on one tracing does not prove that a pathway is exclusively retrograde.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
15.Which findings indicate dangerous antegrade accessory-pathway conduction?
A manifest pathway becomes dangerous when it can transmit atrial fibrillation rapidly to the ventricles. A shortest pre-excited RR interval of 250 ms or less during AF, or an accessory-pathway effective refractory period of 250 ms or less, identifies high-risk electrophysiological properties. Multiple pathways and inducible pathway-mediated tachycardia also matter. Abrupt loss of pre-excitation during testing suggests poorer antegrade conduction but does not provide absolute reassurance. In pre-excited AF, isolated AV nodal blockade can favour hazardous pathway conduction.
Apply it
An irregular broad-complex rhythm shows changing QRS morphology and a shortest clearly pre-excited RR interval of 220 ms. Recognise rapid pathway conduction and select management appropriate to pre-excited AF, with electrical cardioversion when haemodynamic instability is present.
Common pitfall: Measuring an average ventricular rate can conceal very short pre-excited intervals. A familiar AF rate-control drug may be inappropriate when antegrade accessory-pathway conduction is present.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
16.What does a His-refractory ventricular premature beat establish about accessory connections and tachycardia participation?
A ventricular premature beat delivered during confirmed His refractoriness can demonstrate an accessory connection capable of accessing the tachycardia if it reproducibly resets or terminates the rhythm. Termination without subsequent atrial activation ordinarily supports AVRT in the appropriate electrophysiological context, but does not independently establish an obligatory accessory-pathway limb. AVNRT can also be accessed and terminated through a bystander concealed nodoventricular or nodofascicular connection. The essential distinction is between demonstrating access to a circuit and demonstrating that the connection is required for each tachycardia cycle.
Apply it
After a His-refractory ventricular premature beat terminates SVT without another atrial electrogram, verify ventricular capture, His refractoriness and adequate recordings. Then assess the complete response and other maneuvers. Continued tachycardia despite demonstrated His dissociation or AV block that interrupts the expected atrioventricular circuit excludes conventional AVRT. Delayed termination one cycle after the premature beat is another discriminating observation that can support concealed penetration of AVNRT through a bystander connection; interpret it alongside the intervening His and atrial timing.
Common pitfall: Do not label every ventricularly accessible tachycardia as accessory-pathway-dependent reentry. A primary clinical series documents AVNRT accessed through bystander concealed nodoventricular or nodofascicular connections: https://pmc.ncbi.nlm.nih.gov/articles/PMC10848616/. Conversely, an ineffective premature beat does not exclude AVRT because its timing, distance from the pathway and tissue refractoriness can prevent circuit penetration. Atrial advancement alone can also reveal a bystander connection without establishing tachycardia dependence.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia · Hirao_1996.pdf
17.How should para-Hisian atrial tachycardia be mapped safely?
Earliest atrial activation near the His bundle describes an observed breakout region, not necessarily the safest ablation site. A para-Hisian atrial tachycardia should prompt comparison of right atrial septal, left septal and non-coronary aortic cusp recordings where appropriate. Adjacent structures may offer earlier activation or a safer approach away from compact AV nodal tissue. Establish that the rhythm is atrial tachycardia, assess catheter stability and local His signals, and weigh timing against the risk of AV block.
Apply it
A focal atrial tachycardia appears earliest beside a prominent His potential. Before applying energy there, compare activation in adjacent septal and non-coronary cusp sites to identify a potentially safer target with convincing timing and suitable anatomical separation.
Common pitfall: The earliest right atrial signal is not automatically the optimal target. Immediate ablation beside a His potential can create avoidable AV block without proving the true origin.
Management of patients with atrial tachycardia: an EHRA clinical consensus statement
18.How can localized atrial reentry mimic a focal source?
A localized reentrant circuit can produce centrifugal atrial activation from a small breakout region, resembling an automatic or triggered focus on a low-resolution map. Long fractionated local electrograms, continuous activity and pacing responses can reveal a confined circuit. By contrast, true focal activation originates from a discrete source and spreads outward without a demonstrable reentrant loop. Mechanism matters because a narrow slow-conduction isthmus may be the effective target in localized reentry, rather than simply the earliest apparent breakout.
Apply it
A map appears centrifugal, but a small scar border contains prolonged fractionated signals spanning much of the cycle. Increase mapping resolution and assess entrainment before labelling the rhythm automatic and ablating only the earliest visible breakout site.
Common pitfall: Centrifugal activation is a pattern, not a mechanism. Sparse sampling can hide a small circuit and make localized reentry look indistinguishable from a focal atrial source.
Management of patients with atrial tachycardia: an EHRA clinical consensus statement
Ventricular tachycardias15–20%
19.Why does infarct scar support sustained monomorphic VT?
Healed infarct scar contains surviving myocardial bundles separated by fibrosis. These channels conduct slowly and can support unidirectional block and reentry around electrically inert tissue. A relatively fixed exit produces a reproducible monomorphic QRS pattern. Diastolic potentials, entrainment and activation mapping help identify channel participation. The visible exit is not always the critical isthmus: interrupting a protected slow-conduction corridor can abolish the circuit more effectively than targeting the earliest surface-QRS-associated activation alone during sustained ventricular tachycardia.
Apply it
A patient with previous myocardial infarction develops reproducible monomorphic VT. A scar channel contains mid-diastolic electrograms and concealed entrainment. Integrate those findings to identify a likely protected circuit segment rather than treating the QRS morphology as evidence of a focal mechanism.
Common pitfall: Monomorphic appearance does not imply automaticity. An early ventricular breakout can identify a circuit exit while missing the protected isthmus that sustains scar-related reentry.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
20.What suggests idiopathic outflow-tract ventricular tachycardia?
Idiopathic outflow-tract ventricular arrhythmias commonly reflect cyclic-AMP-mediated calcium loading and delayed afterdepolarisations. Exercise or adrenergic stimulation may provoke them, and adenosine sensitivity can support this triggered mechanism. A left bundle branch block pattern with an inferior axis often suggests a right ventricular outflow-tract origin, but neighbouring left-sided structures can produce similar patterns. Apparently idiopathic morphology must still be assessed for structural disease, particularly when imaging, family history or accompanying ECG abnormalities are concerning for another substrate.
Apply it
A young adult has exercise-associated monomorphic ectopy with an inferior axis and left bundle branch block configuration. Use the ECG to plan initial mapping, while reviewing imaging and clinical features before classifying the arrhythmia as idiopathic RVOT disease.
Common pitfall: A typical outflow-tract morphology does not exclude cardiomyopathy. Surface localisation is approximate because adjacent chambers and preferential conduction can produce similar QRS patterns from different origins.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias · 2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
21.How does fascicular VT differ from other idiopathic VT?
Common left posterior fascicular VT is a Purkinje-related reentrant rhythm, typically producing a right bundle branch block configuration with a superior or leftward axis and a relatively narrow ventricular tachycardia QRS. Verapamil sensitivity is characteristic in an established diagnosis. Mapping may identify diastolic and presystolic Purkinje potentials. Distinguishing the circuit from ordinary myocardial activation guides ablation while limiting conduction-system injury. Verapamil responsiveness is a mechanistic clue, rather than permission to administer it to an undifferentiated unstable wide-complex tachycardia.
Apply it
A stable patient with a structurally normal heart has recurrent VT with right bundle branch block morphology and a superior axis. Review Purkinje activation and prior documented responses when assessing fascicular reentry rather than assuming every idiopathic VT arises in an outflow tract.
Common pitfall: Empirical verapamil for an uncertain wide-complex tachycardia can be dangerous. The characteristic fascicular pattern supports a diagnosis only when the wider clinical and electrophysiological evidence fits.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
22.Which findings support bundle branch reentrant VT?
Bundle branch reentry uses the His–Purkinje system as a macroreentrant circuit, often in patients with conduction disease and structural heart disease. A His or bundle potential typically precedes ventricular activation, and changes in His–His intervals preceding corresponding ventricular-cycle changes support conduction-system participation. A His signal alone is insufficient because it may be activated passively. Demonstrating obligatory bundle conduction and appropriate activation relationships is central. Bundle ablation can interrupt the circuit but may create clinically important AV block.
Apply it
During a fast wide-complex tachycardia, spontaneous His–His changes consistently precede ventricular-cycle changes, and block in a participating bundle terminates the rhythm. Consider bundle branch reentry and assess baseline conduction reserve before selecting a bundle ablation strategy.
Common pitfall: Seeing a His potential before every QRS does not alone establish bundle branch reentry. Passive conduction-system activation and supraventricular rhythms with aberrancy require exclusion using additional relationships.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
23.When is activation mapping most useful during VT?
Activation mapping relates local electrograms to the tachycardia cycle and can identify earliest activation in focal VT or diastolic circuit activity in reentrant VT. It is most informative when the rhythm is sustained, sufficiently stable and safely tolerated. Haemodynamically intolerant or nonsustained rhythms may require substrate-based approaches instead. Timing must distinguish near-field activation from far-field signals, and an apparently early point may be a breakout from deeper tissue rather than the actual arrhythmia source or critical circuit segment.
Apply it
A sustained idiopathic VT is haemodynamically tolerated. Build a detailed activation map around the suspected origin and confirm local electrogram quality. If hypotension develops, stop prolonged mapping and reconsider an approach that does not depend on sustained tachycardia.
Common pitfall: Continuing unstable VT merely to complete a map adds risk. The earliest recorded surface location may represent breakout from an intramural or remote source rather than its origin.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
24.What can a good ventricular pace map establish?
Pace mapping compares the paced QRS with the clinical ventricular arrhythmia. A close match supports a similar ventricular activation exit, particularly when spontaneous ectopy is sparse. It does not necessarily identify the exact origin or a critical scar isthmus, because pacing output, captured tissue volume and preferential conduction affect morphology. Stimulus-to-QRS latency and responses across neighbouring points add information. A broad region of good matches should prompt scrutiny rather than unjustified confidence in a single precise target.
Apply it
Several neighbouring scar sites produce nearly identical paced QRS complexes. Compare stimulus-to-QRS delays and abnormal electrograms rather than selecting the visually best match alone; multiple sites may access the same exit through a surviving conduction channel.
Common pitfall: A perfect pace-map match can identify an exit shared by different upstream sites. High-output capture may also obscure the spatial relationship between the catheter and arrhythmogenic tissue.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
25.How does substrate mapping support ablation of unstable VT?
Substrate mapping seeks arrhythmogenic scar characteristics during sinus rhythm or pacing when sustained VT cannot be mapped safely. Late potentials, local abnormal ventricular activities and conducting channels can identify surviving tissue with delayed or abnormal activation. Their relationship to clinical VT varies, so imaging, electrogram behaviour and pacing information should be integrated. Endocardial mapping may miss epicardial or intramural circuits. The purpose is to interrupt plausible reentrant pathways while recognising that every abnormal electrogram is not necessarily an indispensable circuit component.
Apply it
A patient’s clinical VT causes immediate hypotension. In sinus rhythm, map scar channels and delayed potentials, review CMR substrate and plan targeted substrate modification rather than repeatedly inducing prolonged unstable VT solely to obtain an activation map.
Common pitfall: Normal endocardial voltage does not exclude deeper scar. Conversely, extensive abnormal substrate does not establish that every abnormal signal must be ablated to achieve a useful endpoint.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
26.How should VT ablation endpoints be interpreted?
Noninducibility of the clinical VT after ablation is a useful endpoint, and eliminating abnormal substrate may provide complementary evidence. Its meaning depends on the stimulation protocol, medications, sedation and the rhythms inducible before treatment. Noninducibility does not guarantee freedom from recurrence, particularly with progressive disease or inaccessible substrate. Conversely, residual inducibility of a nonclinical rhythm needs contextual interpretation. Endpoint selection should therefore link the treated mechanism, procedural safety and documented pre-ablation arrhythmias rather than rely on an isolated binary result.
Apply it
Clinical VT is no longer inducible after scar-channel ablation, but only a very aggressive protocol induces a different morphology. Compare the pre-ablation study, substrate findings and patient risk before interpreting the result as either complete success or definite failure.
Common pitfall: Declaring a cure from noninducibility ignores protocol dependence and disease progression. Treating every induced nonclinical rhythm as equivalent to the presenting VT can also misdirect further ablation.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
27.How should electrical storm be assessed mechanistically?
Electrical storm describes recurrent sustained ventricular arrhythmias requiring intervention, conventionally at least three episodes within 24 hours separated by at least five minutes. Initial assessment distinguishes true VT or VF from inappropriate device therapy and identifies reversible contributors such as ischaemia, electrolyte disturbance, decompensated heart failure and proarrhythmic drugs. Monomorphic scar VT and recurrent trigger-mediated VF imply different ablation targets. Sympathetic activation can perpetuate episodes, making stabilisation and trigger assessment integral to a mechanism-based treatment plan.
Apply it
An ICD recipient receives repeated shocks overnight. Review stored electrograms before assuming recurrent VT, then assess potassium, ischaemia, heart failure and medication changes. Distinguish repeated monomorphic scar VT from noise-driven therapies or recurrent polymorphic arrhythmia with a consistent trigger.
Common pitfall: Counting shocks without reviewing electrograms can misclassify lead noise as electrical storm. Focusing only on ablation may also miss a reversible precipitant sustaining genuine ventricular arrhythmia.
2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
Specific ablation aspects10–15%
28.Why can irrigated radiofrequency ablation still cause a steam pop?
Radiofrequency energy produces resistive heating near the electrode and conductive heating deeper in tissue. Irrigation cools the electrode–tissue interface and reduces surface coagulum, but does not directly report the hottest intramyocardial temperature. Deep tissue can vaporise, causing a steam pop and potentially perforation. Power, duration, contact, tissue thickness and impedance behaviour all matter. A low displayed catheter temperature therefore does not justify unlimited energy delivery or exclude excessive tissue heating during an apparently stable irrigated application.
Apply it
During irrigated RF delivery, electrode temperature remains modest while impedance falls rapidly and contact is high. Reassess energy delivery and tissue-heating risk rather than increasing power simply because the displayed temperature has not reached a high value.
Common pitfall: Equating electrode temperature with intramural temperature is misleading during irrigation. Audible steam pops are not required for perforation, and apparent catheter stability does not eliminate thermal injury risk.
2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
29.How does cryothermal energy create an ablation lesion?
Cryothermal ablation removes heat, producing ice formation, osmotic injury and microvascular damage as tissue freezes and thaws. Tissue adhesion can improve catheter stability, and limited-temperature cryomapping may allow functional assessment near sensitive conduction tissue before a permanent lesion is attempted. Reversibility is not absolute, however, and full cryoablation can still cause lasting injury. Its biophysics differs from radiofrequency heating, so lesion formation and safety cannot be inferred from RF temperature or impedance rules alone during a cryothermal procedure.
Apply it
When treating a substrate close to the AV conduction system, a team considers cryomapping to assess the effect on conduction before a permanent freeze. Continue monitoring AV conduction because apparent reversibility does not guarantee freedom from lasting block.
Common pitfall: Calling cryothermal ablation risk-free near the AV node overstates its safety. Catheter adhesion improves stability but does not prevent injury to neighbouring conduction or neural structures.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia · 2024 EHRA/HRS/APHRS/LAHRS expert consensus statement on catheter and surgical ablation of atrial fibrillation
30.How does pulsed field ablation differ from thermal ablation?
Pulsed field ablation applies electric fields that destabilise cell membranes through electroporation; sufficiently intense exposure produces irreversible injury. Its principal intended mechanism is nonthermal, and myocardial selectivity may reduce some collateral injuries associated with thermal AF ablation. Safety and efficacy nevertheless depend on waveform, electrode geometry, contact and delivered field. Vascular injury, tamponade, embolic complications and other platform-specific hazards remain possible. Evidence for one device or lesion set cannot automatically be transferred to every pulsed-field system or anatomical application.
Apply it
A patient asks whether pulsed field AF ablation eliminates procedural risk. Explain its electroporation mechanism and potential collateral-tissue advantages while identifying residual access, perforation and thromboembolic risks that require the same careful procedural assessment and surveillance.
Common pitfall: Nonthermal describes the dominant mechanism, not a guarantee of zero heating or complications. Results from one pulsed-field platform do not establish interchangeable performance across all systems.
31.Why is imaging valuable during transseptal access?
Transseptal puncture aims to cross the fossa ovalis into the left atrium while avoiding the aortic root and free atrial walls. Intracardiac or transoesophageal echocardiography can identify septal anatomy, needle tenting and adjacent structures, particularly when anatomy is distorted or prior interventions alter landmarks. Pressure and other procedural observations complement imaging. Confirming safe left atrial entry before advancing equipment is essential because an apparently plausible fluoroscopic position does not by itself prove correct tissue engagement or chamber access.
Apply it
In a patient with an enlarged atrium and distorted septal landmarks, use echocardiography to confirm fossa-ovalis tenting and the relationship to the aorta before puncture. Confirm chamber entry before advancing a dilator or large sheath through the septum.
Common pitfall: Fluoroscopic silhouette alone can be misleading in altered anatomy. Advancing equipment after uncertain puncture can convert a small misplacement into major perforation or aortic injury.
32.How does ultrasound-guided venous access reduce avoidable injury?
Ultrasound visualises the vessel, adjacent artery, needle entry and anatomical variation during femoral venous access. This can reduce inadvertent arterial puncture and other access complications compared with reliance on surface landmarks alone. The guidewire course and subsequent sheath placement still require verification. After the procedure, haemostasis must account for sheath size, anticoagulation and the access technique. New groin swelling, pain, haemodynamic change or falling haemoglobin warrants assessment for bleeding rather than automatic attribution to an expected post-procedural bruise.
Apply it
A heavily anticoagulated patient requires multiple femoral venous sheaths. Use ultrasound to identify the vein and adjacent artery, minimise puncture attempts, and plan haemostasis. Afterward, investigate expanding swelling or unexplained hypotension promptly rather than relying only on skin appearance.
Common pitfall: Successful venous entry does not guarantee safe wire or sheath positioning. A small visible bruise also cannot exclude deeper bleeding when symptoms or haemodynamics are concerning.
33.Which measures reduce radiation without weakening procedural guidance?
Radiation exposure can be reduced by minimising fluoroscopy time, using low pulse rates, collimating the field, avoiding unnecessary magnification and choosing less irradiating projections when feasible. Electroanatomic mapping and intracardiac echocardiography provide complementary navigation and anatomical information. Staff shielding and distance remain important when fluoroscopy is used. A low-fluoroscopy approach requires reliable localisation and imaging skills; radiation reduction should preserve the information needed for safe catheter movement, anatomical interpretation and recognition of complications throughout the procedure.
Apply it
During left atrial ablation, combine mapping and intracardiac imaging for navigation, reserving brief collimated fluoroscopy for unresolved positional questions. Review dose information as well as fluoroscopy time because projection, patient size and system settings influence actual exposure.
Common pitfall: Fluoroscopy time alone is an incomplete dose measure. Eliminating imaging without an adequate alternative can sacrifice essential anatomical information even if the recorded radiation exposure falls.
34.How can impending phrenic nerve injury be recognised?
The right phrenic nerve lies near right pulmonary venous and superior caval structures, creating vulnerability during nearby ablation. Phrenic pacing with observation of diaphragmatic contraction and, when used, compound motor action potential monitoring can reveal weakening before complete palsy. A reduction in diaphragmatic response should trigger immediate reassessment and interruption of injurious energy delivery. Monitoring depends on stable pacing capture and reliable observation, so loss of response must be distinguished from displacement of the pacing catheter or loss of capture.
Apply it
During right-sided cryoballoon treatment, diaphragmatic contraction weakens despite maintained phrenic pacing capture. Stop the application promptly and assess nerve function rather than waiting for complete paralysis or assuming that a previously normal response guarantees continued safety.
Common pitfall: Waiting for total loss of diaphragmatic movement can miss an earlier warning. Apparent weakness also requires checking pacing capture so a technical failure is not misinterpreted as nerve injury.
35.When should atrio-oesophageal fistula be suspected after AF ablation?
Oesophageal injury after left atrial thermal ablation can progress to atrio-oesophageal fistula, often presenting days to weeks later with fever, chest discomfort, dysphagia, gastrointestinal bleeding or neurological symptoms. The delayed interval does not make a procedural link unlikely. Suspected fistula requires urgent specialist assessment and appropriate chest CT imaging. Endoscopy with air insufflation is hazardous because communication with the left atrium can cause systemic air embolism. A nondiagnostic initial study does not end evaluation when clinical suspicion remains strong.
Apply it
Two weeks after AF ablation, a patient develops fever and a transient neurological deficit with painful swallowing. Treat the combination as a possible atrio-oesophageal fistula, arrange urgent specialist evaluation and chest imaging, and avoid routine diagnostic endoscopy with insufflation.
Common pitfall: Labelling delayed fever as an unrelated infection can miss a lethal complication. Routine endoscopy is not a benign first test when an atrio-oesophageal communication is suspected.
Atrial flutter and Atrial Fibrillation15–20%
36.Why is pulmonary vein isolation central to AF ablation?
Myocardial sleeves extending into pulmonary veins commonly generate triggers that initiate AF. Pulmonary vein isolation electrically disconnects these sleeves from the left atrium rather than merely suppressing a visible ectopic beat. It is the foundational lesion strategy for AF ablation, although atrial substrate and non-pulmonary-vein triggers can contribute, especially in more advanced disease. Procedural success therefore requires demonstrating electrical isolation, while recognising that isolation alone does not guarantee permanent freedom from AF or eliminate the need for comprehensive clinical management.
Apply it
A patient’s AF repeatedly begins after pulmonary venous ectopy. Explain why circumferential electrical isolation addresses trigger transmission even when no ectopy occurs during the procedure. Confirm a conduction endpoint rather than using the absence of observed triggers as proof of success.
Common pitfall: A visually complete lesion ring does not prove electrical isolation. Conversely, AF recurrence after apparently successful isolation does not automatically mean that the original mechanism was incorrectly identified.
37.How are pulmonary vein entrance and exit block distinguished?
Entrance block means left atrial activation no longer conducts into pulmonary venous myocardium, demonstrated by disappearance or dissociation of genuine pulmonary vein potentials. Exit block means captured pulmonary venous myocardium cannot conduct outward to the atrium. Exit testing requires confirmed local sleeve capture and exclusion of direct atrial capture. Far-field atrial signals can mimic residual pulmonary venous potentials. Recognising these distinctions prevents both false declarations of isolation and unnecessary additional ablation based on signals arising outside the vein.
Apply it
After isolation, a circular catheter records a small signal near a left pulmonary vein. Compare its timing and pacing responses with adjacent atrial structures before calling reconnection. During exit testing, confirm sleeve capture before interpreting absent atrial activation as exit block.
Common pitfall: Failure to capture the pulmonary venous sleeve cannot demonstrate exit block. Far-field appendage or atrial signals may also persist despite genuine entrance block and require careful identification.
38.Why can pulmonary veins reconnect after initially successful isolation?
Acute conduction block may reflect reversible oedema or transient cellular injury around an incomplete durable lesion. As tissue recovers, surviving gaps can reconnect the pulmonary venous sleeves to the atrium. Reconnection is an important mechanism of recurrent AF, but it is not the only one: progressive atrial substrate and non-pulmonary-vein triggers also contribute. At repeat procedures, systematic conduction assessment identifies whether reisolation is needed rather than assuming every vein remains isolated or every recurrence has the same mechanism.
Apply it
A patient has recurrent AF months after documented acute isolation. At a repeat procedure, assess each vein’s conduction and localise gaps before adding unrelated atrial lines. If isolation persists, broaden the mechanistic assessment instead of delivering empirical repeat lesions everywhere.
Common pitfall: Acute electrical silence does not guarantee durable tissue destruction. Recurrent symptoms also need rhythm documentation because atrial tachycardia, ectopy or nonarrhythmic symptoms may mimic recurrent AF.
39.What makes typical flutter CTI-dependent?
Typical atrial flutter is macroreentry around the tricuspid annulus using the cavotricuspid isthmus as an obligatory passage. Counterclockwise activation commonly produces negative inferior flutter waves and a positive component in V1, but prior surgery, atrial disease or altered activation can change the ECG. Demonstrating CTI participation with activation and entrainment is more specific than surface morphology alone. Ablation interrupts the inferior isthmus between the tricuspid annulus and inferior vena cava, with conduction block as the essential endpoint.
Apply it
A patient has an ECG compatible with typical flutter. During EP study, show activation around the tricuspid annulus and entrainment findings consistent with CTI participation. Use the mechanism to justify the lesion location rather than relying exclusively on flutter-wave appearance.
Common pitfall: Atypical ECG morphology does not exclude CTI dependence after prior intervention. Conversely, an apparently typical surface pattern cannot prove that the CTI is obligatory in every patient.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
40.Why is bidirectional CTI block required after flutter ablation?
Flutter termination can result from transient conduction slowing or block without a durable complete lesion. Bidirectional CTI block demonstrates failure of conduction across the ablation line in both directions, forcing activation to travel around the tricuspid annulus. Pacing from opposite sides, activation-sequence assessment and differential pacing help distinguish true block from very slow residual conduction. Split local potentials support the interpretation but require context. The endpoint tests the required anatomical barrier rather than simply the absence of ongoing flutter.
Apply it
CTI ablation terminates flutter. Continue assessment by pacing from both sides of the line and examining activation detours and differential pacing responses. Do not conclude the procedure solely because sinus rhythm has returned and flutter is temporarily noninducible.
Common pitfall: Termination is an event, whereas bidirectional block is a conduction endpoint. A long conduction delay across an incomplete line can imitate block unless pacing and activation sequences are assessed carefully.
2019 ESC Guidelines for the management of patients with supraventricular tachycardia
41.How is atypical macroreentrant flutter defined?
Atypical macroreentrant atrial tachycardia uses a large circuit outside the usual CTI-dependent loop, often around scars, valve annuli or prior ablation lines. Activation mapping should account for the cycle and demonstrate a coherent circuit rather than an apparent earliest point alone. Entrainment from selected sites tests participation, while anatomical obstacles identify possible protected isthmuses. Previous left atrial ablation raises suspicion for roof-dependent or perimitral circuits, but chamber and circuit location require direct evidence rather than inference from procedure history.
Apply it
Following AF ablation, a patient develops regular atrial tachycardia. Map both plausible chambers as indicated, account for the full cycle and use entrainment to test suspected loops before choosing a roof, mitral-isthmus or other connecting lesion.
Common pitfall: Previous left atrial ablation does not prove a left atrial circuit. A colour map with an early-meets-late boundary can also mislead when timing windows or annotation are incorrect.
Management of patients with atrial tachycardia: an EHRA clinical consensus statement
42.Why can incomplete atrial lines create new tachycardias?
A partially conducting ablation line can create a narrow slow-conduction passage bounded by scar. That arrangement promotes organised reentry even when the original intention was to interrupt a larger circuit. A gap may appear as prolonged, fractionated local activity with activation traversing the line. Targeting the critical gap can terminate the tachycardia, but the completed line should then be tested for block. Additional empirical lines increase complexity and may create further potential channels if their conduction endpoints are not achieved.
Apply it
A regular atrial tachycardia follows a prior roof line. Mapping shows a narrow conducting gap with delayed electrograms. Determine whether the gap is an obligatory circuit segment, ablate it if appropriate, and verify conduction block across the completed line.
Common pitfall: Adding another line before understanding the existing circuit can create additional proarrhythmic gaps. Tachycardia termination at one gap does not by itself prove durable block across the entire line.
Management of patients with atrial tachycardia: an EHRA clinical consensus statement · 2024 EHRA/HRS/APHRS/LAHRS expert consensus statement on catheter and surgical ablation of atrial fibrillation
43.How long is anticoagulation continued immediately after AF ablation?
The 2024 ESC AF guideline recommends oral anticoagulation for at least two months after AF catheter ablation, regardless of estimated thromboembolic risk or apparent rhythm success. The early post-procedural period includes thrombogenic effects from atrial injury and transient mechanical or rhythm disturbances. Longer-term treatment is then determined by the patient’s thromboembolic risk rather than presumed procedural success. This separates a universal early post-ablation recommendation from the subsequent individual risk-based decision and prevents premature withdrawal in apparently well patients.
Apply it
A low-risk patient is in sinus rhythm one week after AF ablation and asks to stop anticoagulation. Explain the minimum early treatment period and arrange later reassessment rather than treating immediate rhythm success as a reason for early discontinuation.
Common pitfall: Absence of palpitations does not remove early post-ablation thrombotic risk. The minimum two-month recommendation also does not mean that every patient should stop anticoagulation at that point.
2024 ESC Guidelines for the management of atrial fibrillation
44.How is CHA2DS2-VA used after AF ablation?
CHA2DS2-VA assigns one point each for heart failure, hypertension, diabetes, vascular disease and age 65–74, and two each for age at least 75 and previous stroke, TIA or arterial thromboembolism. Sex is excluded. Under the 2024 ESC approach, anticoagulation is recommended at a score of at least two and should be considered at one. After ablation, this clinical risk assessment governs long-term treatment rather than apparent maintenance of sinus rhythm. Reassessment matters because age and comorbidities change.
Apply it
A 68-year-old patient with hypertension and no other listed factors has a CHA2DS2-VA score of two. Even after apparently successful ablation, the risk-based approach supports continued long-term anticoagulation rather than stopping treatment because monitoring shows sinus rhythm.
Common pitfall: Adding a sex-category point mixes CHA2DS2-VASc with CHA2DS2-VA. Successful rhythm control also does not erase age, prior stroke or vascular comorbidity from thromboembolic risk assessment.
2024 ESC Guidelines for the management of atrial fibrillation
45.How does AF-CARE shape ablation assessment?
AF-CARE organises care around comorbidity and risk-factor management, avoidance of stroke and thromboembolism, reduction of symptoms through rate and rhythm control, and evaluation with dynamic reassessment. Ablation fits within rhythm control rather than replacing the other components. Assessing heart failure, blood pressure, obesity, sleep-disordered breathing, alcohol exposure and anticoagulation helps address drivers and consequences of AF. Shared decisions should connect symptoms, expected benefit, procedural risk and the need for continuing reassessment as the patient’s circumstances change.
Apply it
An obese patient with poorly controlled hypertension seeks immediate repeat ablation for recurrent AF. Discuss rhythm-control options while also addressing blood pressure, weight, possible sleep apnoea and stroke prevention, then reassess symptoms and rhythm burden over time.
Common pitfall: Treating ablation as a complete AF care plan overlooks modifiable drivers and stroke prevention. Risk-factor management complements indicated rhythm control rather than automatically replacing it in every symptomatic patient.
2024 ESC Guidelines for the management of atrial fibrillation: official guideline page · 2024 ESC Guidelines for the management of atrial fibrillation
Clinical rhythmology (ECGs, imaging, clinical syndroms and related technics)10–15%
46.Which ECG findings strongly support VT in a wide-complex rhythm?
AV dissociation, capture beats and fusion beats strongly support ventricular tachycardia when correctly identified. A capture beat reflects a supraventricular impulse activating the ventricle during VT; a fusion beat combines ventricular activation from competing sources. Prior infarction or structural heart disease increases the likelihood of VT. Haemodynamic stability does not establish a supraventricular mechanism, and a one-to-one VA relationship does not exclude VT because retrograde conduction may be present. Integrate specific ECG signs with morphology and clinical context.
Apply it
A stable patient with previous infarction has regular wide-complex tachycardia and occasional normal-looking beats occurring after independent P waves. Identify possible capture beats and prioritise a VT interpretation rather than using preserved blood pressure to classify the rhythm as SVT.
Common pitfall: Stable VT is common enough that blood pressure cannot determine origin. Apparent capture or fusion also requires careful ECG inspection to exclude artefact or ordinary QRS variation.
2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
47.How should rhythm monitoring match symptom frequency?
The diagnostic aim is to correlate a spontaneous symptom with the cardiac rhythm. Frequent daily symptoms may be captured by short Holter monitoring, while less frequent events require longer external monitoring or an implantable loop recorder. Recurrent unexplained syncope occurring months apart is unlikely to be resolved by a single brief recording. Monitoring choice also depends on risk: a patient with evidence of a dangerous cause needs timely targeted evaluation rather than an indiscriminate outpatient wait for another event.
Apply it
A patient has unexplained syncope every four months after an unrevealing initial assessment, without an immediate high-risk indication for admission. Select a monitoring strategy capable of recording infrequent spontaneous events rather than repeatedly ordering short Holter studies between episodes.
Common pitfall: A normal recording without symptoms does not exclude intermittent arrhythmia. Symptom frequency guides monitoring duration, but high-risk clinical findings can require urgent assessment before prolonged ambulatory observation.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
48.What clinical pattern suggests catecholaminergic polymorphic VT?
Catecholaminergic polymorphic VT typically presents with exercise- or emotion-related ventricular arrhythmias in a structurally normal heart and an often normal resting ECG. Exercise testing may show increasing ventricular ectopy, bidirectional VT or polymorphic VT as adrenergic drive rises. Abnormal intracellular calcium handling is central, commonly involving RYR2-associated disease. A normal resting QT interval does not exclude this syndrome. The characteristic trigger–rhythm relationship and family history distinguish it from diagnoses based mainly on resting repolarisation or structural abnormalities.
Apply it
An adolescent has exertional syncope, normal echocardiography and a normal resting ECG. Exercise provokes progressively complex ventricular ectopy and bidirectional VT. Investigate CPVT rather than dismissing the episodes because resting electrical and structural tests appear normal.
Common pitfall: A normal resting ECG cannot exclude an inherited arrhythmia syndrome. Bidirectional VT is suggestive in this setting but also requires exclusion of relevant drug toxicity and other causes.
2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
49.How should prolonged QT be assessed before diagnosing long QT syndrome?
QT assessment requires a reliable tracing, appropriate heart-rate correction and review of medications, electrolytes and other acquired causes. Repeated QTc of at least 480 ms supports a clinical long QT syndrome diagnosis in the appropriate setting; diagnostic scoring and pathogenic variants provide additional routes. Syncope during characteristic triggers and family history strengthen suspicion. A single automated measurement is insufficient when T-wave termination is uncertain or U waves are prominent. Distinguish congenital susceptibility from reversible acquired repolarisation prolongation before interpreting risk.
Apply it
A patient’s automated QTc is prolonged while taking a QT-prolonging drug and having hypokalaemia. Manually review the tracing, correct reversible contributors and reassess before diagnosing congenital long QT syndrome solely from the initial machine-generated measurement.
Common pitfall: Including a separate U wave can falsely lengthen the QT. Conversely, a normal tracing on one occasion does not completely exclude inherited long QT syndrome in a strongly suggestive family.
2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
50.Which ECG pattern meets the type 1 Brugada morphology?
The type 1 Brugada pattern has coved ST elevation of at least 2 mm followed by a negative T wave in at least one right-precordial lead V1 or V2 positioned in the second, third or fourth intercostal space. A saddleback pattern alone does not meet this morphology. Fever, drugs and reversible Brugada-like conditions must be considered. Recognising the ECG pattern is distinct from completing syndrome diagnosis and risk assessment, especially when the finding appears only during pharmacological provocation.
Apply it
During fever, a patient develops coved 3 mm ST elevation with T-wave inversion in V1 recorded in the third intercostal space. Recognise a type 1 pattern and evaluate clinical context and reversible mimics rather than rejecting the high lead position.
Common pitfall: Requiring both V1 and V2 to be positive misses qualifying patterns. Calling any right-precordial saddleback elevation diagnostic also confuses type 1 morphology with less specific findings.
Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes · 2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
51.How does CMR refine ventricular arrhythmia assessment?
Cardiac magnetic resonance adds tissue characterisation to ventricular size and function. Late gadolinium enhancement can identify fibrosis and its distribution, helping distinguish an ischaemic subendocardial or transmural pattern from many nonischaemic patterns. These findings influence whether an arrhythmia is reasonably considered idiopathic and can inform substrate planning. CMR does not directly identify every critical conduction channel, and absence of enhancement does not exclude all disease. Interpret imaging alongside ECG morphology, family history, arrhythmia behaviour and other clinical evidence.
Apply it
A patient labelled as having idiopathic PVCs has atypical morphology and unexplained ventricular dysfunction. Obtain appropriate tissue-characterising imaging; detection of nonischaemic scar changes the substrate assessment and prevents assuming that all ectopy arises from a structurally normal heart.
Common pitfall: Normal echocardiographic dimensions do not exclude myocardial fibrosis. Conversely, an enhancement pattern should not be treated as a complete aetiological diagnosis without supporting clinical information.
2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
52.When should PVC-induced cardiomyopathy be suspected?
Frequent PVCs can cause or aggravate left ventricular dysfunction through repeated abnormal activation and associated mechanical inefficiency. A burden around 10% or greater raises suspicion, with risk generally increasing at higher burdens, but no burden alone proves causation. Assess PVC morphology, variability, structural disease and alternative causes of dysfunction. Improvement in ventricular function after effective PVC suppression supports the diagnosis retrospectively. Scar on CMR may instead suggest underlying cardiomyopathy, although PVCs can still contribute to dysfunction in a diseased heart.
Apply it
A patient has a 24% predominantly monomorphic PVC burden, reduced ejection fraction and no identified alternative cause. Consider PVC-mediated dysfunction and pursue effective suppression while documenting baseline function so subsequent recovery can strengthen the causal assessment.
Common pitfall: High PVC burden and low ejection fraction can coexist without a purely PVC-induced disorder. A single short recording may also misrepresent burden because ectopy varies over time.
2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death · 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
53.How do structural echocardiography and atrial thrombus imaging guide cardioversion and AF ablation?
Transthoracic echocardiography assesses ventricular function, chamber dimensions and valvular disease but cannot reliably exclude left atrial appendage thrombus. For planned cardioversion when AF has lasted more than 24 hours, the 2024 ESC guideline requires at least three weeks of therapeutic anticoagulation beforehand or transoesophageal echocardiography to exclude thrombus and permit earlier cardioversion. Imaging-guided cardioversion still requires appropriate anticoagulation. Pre-ablation assessment is a separate decision: thrombus imaging is reasonable in patients with relevant thromboembolic risk who have not received at least three weeks of therapeutic anticoagulation. Selected patients with higher thrombus risk may warrant imaging despite adequate anticoagulation.
Apply it
A stable patient with AF lasting five days, normal ventricular function on transthoracic echocardiography and only one week of therapeutic anticoagulation is scheduled for cardioversion. Either defer cardioversion until at least three weeks of therapeutic anticoagulation have been completed or use transoesophageal imaging to exclude thrombus before earlier cardioversion. For a patient undergoing AF ablation, assess anticoagulation duration and thromboembolic risk separately; persistent AF or hypertrophic cardiomyopathy can support thrombus imaging even after three weeks of therapeutic anticoagulation.
Common pitfall: A normal ejection fraction does not establish absence of appendage thrombus. Do not automatically transfer the cardioversion timing rule into a universal imaging requirement for every ablation patient. Conversely, three weeks of anticoagulation does not guarantee absence of thrombus in a patient with substantial thrombotic risk. Detection of atrial thrombus prevents proceeding with the planned cardioversion or ablation until it has been appropriately treated and reassessed.
2024 ESC Guidelines for the management of atrial fibrillation · 2024 EHRA/HRS/APHRS/LAHRS expert consensus statement on catheter and surgical ablation of atrial fibrillation
54.How should an ablation study’s endpoint influence its interpretation?
A study showing fewer documented arrhythmia recurrences establishes a different benefit from one demonstrating reduced death, stroke or heart-failure admission. Interpretation requires attention to population, comparator, monitoring intensity, follow-up duration, crossover and the prespecified endpoint. Intermittent monitoring can miss asymptomatic recurrence, while a brief episode threshold may not capture changes in total burden or symptoms. Apply results to patients resembling those studied, and distinguish an efficacy signal from evidence that every downstream clinical outcome improves with the same intervention.
Apply it
An AF ablation trial reports improved freedom from recorded recurrence using intermittent monitoring. Explain the demonstrated rhythm benefit while checking symptom and hospitalisation outcomes separately; do not infer a mortality or anticoagulation benefit that the study did not establish.
Common pitfall: A favourable rhythm endpoint cannot automatically justify stopping anticoagulation. Comparisons across studies can also mislead when recurrence definitions, blanking periods and monitoring intensity differ substantially.
2024 EHRA/HRS/APHRS/LAHRS expert consensus statement on catheter and surgical ablation of atrial fibrillation · 2024 ESC Guidelines for the management of atrial fibrillation
Devices10%
55.Which patients have the clearest conventional CRT indication?
A strong conventional CRT indication is symptomatic heart failure despite optimal medical treatment, sinus rhythm, left ventricular ejection fraction of 35% or less, left bundle branch block morphology and QRS duration of at least 150 ms. QRS width and morphology predict the likelihood of benefit from correcting electrical dyssynchrony. Narrow-QRS systolic dysfunction alone does not establish this indication. Other pacing and AF scenarios require their own criteria, including the ability to achieve effective biventricular capture rather than simply implanting a device.
Apply it
A patient remains symptomatic despite appropriate heart-failure treatment, with ejection fraction 30%, sinus rhythm and LBBB measuring 165 ms. Recognise a strong CRT profile, then assess procedural suitability and whether separate indications support a defibrillator component.
Common pitfall: Low ejection fraction alone does not determine CRT eligibility. CRT-P versus CRT-D is also a separate decision that cannot be resolved solely from QRS duration.
2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
56.Why does an ICD magnet not protect a pacing-dependent patient from inhibition?
For most ICD systems, magnet application suspends tachyarrhythmia detection or therapy but does not change bradycardia pacing to an asynchronous mode. Electromagnetic interference may therefore still be oversensed and inhibit pacing in a pacing-dependent patient. When the procedure and dependence require asynchronous support, explicit programming is needed alongside management of tachyarrhythmia therapies. Device-specific magnet behaviour must be verified, and external monitoring and defibrillation capability maintained while ICD therapy is disabled. Therapy restoration is an essential post-procedural step.
Apply it
A pacing-dependent ICD recipient requires surgery with significant electrocautery interference near the device. Plan appropriate pacing-mode programming and temporary tachytherapy management rather than relying on a magnet alone to prevent bradycardic pauses during the operation.
Common pitfall: Transferring a pacemaker magnet assumption to an ICD can leave pacing inhibition unaddressed. Magnet response also varies by device and programming, so presumed behaviour requires verification.
57.How can T-wave oversensing be distinguished from lead noise?
T-wave oversensing produces an additional sensed event linked to ventricular repolarisation, often creating alternating R-to-T and T-to-R intervals and an artificially doubled rate. Lead noise more often produces nonphysiological rapid signals, sometimes with discrepancies between near-field and far-field channels or changes related to movement. Neither diagnosis should rest on a rate counter alone. Review stored electrograms, sensing markers, lead measurements and reproducibility. Stable impedance does not exclude intermittent lead failure, and T-wave oversensing can occur without structural lead damage.
Apply it
An ICD records an apparent ventricular rate twice the actual rate. Stored electrograms show each extra sensed marker consistently aligned with the T wave. Investigate repolarisation oversensing before diagnosing true VT or assuming that the lead must be fractured.
Common pitfall: Normal lead impedance does not exclude intermittent noise. Conversely, every inappropriate fast detection is not a lead fracture; timing relative to the cardiac cycle can identify T-wave oversensing.
58.How does antitachycardia pacing terminate monomorphic VT?
Antitachycardia pacing delivers a brief sequence faster than the tachycardia to enter a reentrant circuit’s excitable gap and interrupt propagation. It can terminate many monomorphic VTs without a painful shock. Success depends on rhythm mechanism, cycle length, pacing access and programmed sequence; acceleration can occur. ATP is not a treatment for every rapid ventricular rhythm and should be integrated with appropriate detection and shock backup. Stored electrograms help confirm whether an apparent success represents true termination rather than spontaneous cessation.
Apply it
An ICD recipient has recurrent haemodynamically tolerated monomorphic VT repeatedly terminated by ATP. Review detection and ATP programming to preserve effective painless therapy while maintaining backup shocks and evaluating the underlying arrhythmia burden and need for additional treatment.
Common pitfall: ATP can accelerate VT and does not reliably terminate VF. Successful device termination also does not remove the need to investigate recurrent arrhythmia triggers or progressive disease.
59.Why can longer ICD detection reduce unnecessary therapy?
A detection duration requires a ventricular rhythm to persist before therapy is delivered. Longer evidence-based detection intervals allow some nonsustained ventricular arrhythmias to terminate spontaneously and can reduce avoidable ATP or shocks. Rate thresholds and supraventricular discrimination provide additional protection against inappropriate treatment. Programming must still account for known clinical VT, haemodynamic tolerance and the prevention indication. A monitor-only zone can document selected rhythms, but it should not inadvertently leave a clinically important sustained VT untreated because its rate lies below the treatment zone.
Apply it
Device review shows brief self-terminating ventricular runs receiving therapy under short detection settings. Consider evidence-based longer detection while checking the patient’s documented VT rates and symptoms, rather than simply raising every treatment threshold without regard to clinical arrhythmias.
Common pitfall: Longer detection is not synonymous with ignoring sustained VT. Generic rate cutoffs can miss a patient’s known slower clinical tachycardia if programming is not individualised.
60.How should a stored ICD episode be reviewed before treatment changes?
Episode review should reconstruct onset, atrial and ventricular timing, electrogram morphology, sensing markers, detection criteria and delivered therapy. Determine whether the event was ventricular arrhythmia, supraventricular rhythm, oversensing or another device problem before changing medication or programming. Compare near-field and far-field channels when available, and inspect what happened after ATP or shock. A device’s diagnostic label reflects programmed algorithms, not an independent clinical diagnosis. The resulting interpretation should explain both the underlying rhythm and why the device responded as recorded.
Apply it
A patient reports a shock labelled VF by the device. Review electrograms and markers before escalating antiarrhythmic therapy. If nonphysiological sensed signals triggered detection during an otherwise stable rhythm, investigate sensing or lead problems rather than treating presumed recurrent VF.
Common pitfall: Accepting the episode label without electrogram review can lead to inappropriate drugs or ablation. A successful shock also does not prove that the preceding detection represented true ventricular arrhythmia.
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Build mechanism tables linking surface ECG findings, atrial–His–ventricular sequences and pacing responses; distinguish a suggestive pattern from evidence of obligatory circuit participation.
- Prioritise SVT, VT and atrial flutter/AF while preserving coverage of basic electrophysiology, mapping principles, procedural safety, clinical assessment and devices.
- Practise the numerical decisions that change interpretation: accessory-pathway conduction at 250 ms or less, CHA2DS2-VA scoring, conventional CRT criteria and postpacing-interval comparisons.
- Separate rhythm termination from validated endpoints: pulmonary vein conduction block, bidirectional CTI block and context-dependent VT noninducibility.
- Recognise urgent complications from timing and presentation, especially delayed atrio-oesophageal fistula, tamponade, access bleeding and phrenic dysfunction.
- Use the complete official outline and updated EHRA curriculum to identify topics beyond this selective guide, and read the relevant clinical guidance for recommendation details.
A practical preparation plan
1. Map the full scope
Create a study tracker using the eight official domains and their published ranges. Add the complete current EHRA curriculum beneath it; use the 60 concepts as an initial framework rather than a substitute for that scope.
2. Draw the circuits
Sketch typical and atypical AVNRT, orthodromic and antidromic AVRT, scar VT, bundle branch reentry and common atrial macroreentry. Mark obligatory structures, expected activation sequences and which premature beat or pacing response could challenge each diagnosis.
3. Interpret recordings before naming rhythms
For each tracing, identify capture, local versus far-field signals, AH/HV or VA relationships, and the timing reference. Explain what the observation establishes and what additional evidence is needed before choosing an ablation target.
4. Attach endpoints and hazards
Pair every procedure with a measurable endpoint and its principal safety boundaries. Rehearse pulmonary vein isolation testing, CTI differential pacing, VT endpoint limitations, transseptal confirmation and device management during interference.
5. Complete and analyse the drills
Answer the 20 questions without viewing explanations. Classify errors as mechanism, measurement, clinical criteria or unsafe inference, then write why each competing option fails. This small set measures learning opportunities rather than certification readiness.
6. Revisit guidance and recall
Use the flashcards for spaced recall, then return to the cited guidance when reasoning remains uncertain. Before examination registration, review the issuer’s current format, blueprint links and programme requirements for changes.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- EHRA Certification in Invasive Cardiac Electrophysiology for Physicians (EP)
- Certification in Invasive Cardiac Electrophysiology (EP): Topics distribution
- EHRA certification: a 15-year journey of attesting excellence in arrhythmia healthcare
- EHRA Certification in Invasive Cardiac Electrophysiology for Allied Professionals (EP/AP)
- EHRA Certifications
- 2019 ESC Guidelines for the management of patients with supraventricular tachycardia
- 2022 ESC Guidelines for ventricular arrhythmias and prevention of sudden cardiac death
- 2019 HRS/EHRA/APHRS/LAHRS expert consensus statement on catheter ablation of ventricular arrhythmias
- Practical compendium of antiarrhythmic drugs: an EHRA clinical consensus statement
- Management of patients with atrial tachycardia: an EHRA clinical consensus statement
- 2024 EHRA/HRS/APHRS/LAHRS expert consensus statement on catheter and surgical ablation of atrial fibrillation
- 2024 ESC Guidelines for the management of atrial fibrillation
- 2024 ESC Guidelines for the management of atrial fibrillation: official guideline page
- 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapy
- EHRA consensus on prevention and management of interference due to medical procedures in patients with cardiac implantable electronic devices
- 2015 HRS/EHRA/APHRS/SOLAECE expert consensus statement on optimal implantable cardioverter-defibrillator programming and testing
- Executive Summary: HRS/EHRA/APHRS Expert Consensus Statement on the Diagnosis and Management of Patients with Inherited Primary Arrhythmia Syndromes
- 2019 ESC Guidelines for the management of patients with supraventricular tachycardia
- EHRA consensus on prevention and management of interference due to medical procedures in patients with cardiac implantable electronic devices
- 9f5b44276f4ccd1e94d020c0f096b5940e35.pdf
- 2015-hrs_ehra_aphrs_solaece-expert-consensus-statement-on-optimal-implantable-cardioverter-defibrillator-programming-and-testing.pdf
- Hirao_1996.pdf
- 80eeaf_96fffe05ff4d4bb09b4346824ea2d469.pdf
- ESC-guideline-on-cardiac-pacing-2021.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.